Director/PDMR Shareholding

RNS Number : 7811K

e-Therapeutics plc

01 August 2013

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Issue of equity and Directors' shareholdings

1 August 2013, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that two Non-Executive Directors of the Company have taken part of their fees for the half-year ended 31 July 2013 in ordinary shares.

The new ordinary shares were issued on 1 August 2013 at a price of 35.25 pence per share, this being the average of the closing mid-market prices for the five business days ending on the last date of the period (31 July 2013). The allotment and total holdings following this allotment are shown below.

Director	Shares allotted 1 August 2013	Ordinary shares held following allotment (% of current issued share capital)	Options over ordinary shares held (% of current issued share capital)
Oliver James	7,660	126,416 (0.05%)	143,020 (0.05%)
Rajesh Chopra	4,445	19,063 (0.01%)	-

Application has been made to admit the 12,105 new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 7 August 2013. Following admission the number of ordinary shares in issue in the Company will be 263,591,443. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.

Contacts:

e-Therapeutics plc

Daniel Elger

Tel: [phone]

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Corporate Finance: Fred Walsh / Grishma Patel

Corporate Broking: Hannah Woodley

Tel: [phone]

www.panmure.com

 

END

 

 

RDSLLFEETLILIIV